If you are a practicing physician and are interested in treating early-stage COVID-19 patients please register with us using the form down below.
This will enable members of our private association who may have early-stage disease to contact you for treatments that might include a dosing schedule of interferon-alpha and tretinoin analogous to what is used in patients with myeloproliferative disorders like leukemia.
One of these schedules might involve 3 million international units of interferon-alpha administered via subcutaneous injection on alternative days (three times a week) along with about 10 mg of tretinoin taken orally 4 times a day (five days a week). For example a patient may be prescribed:
Interferon-alpha (3 million IU) Monday,Wednesday and Friday
Tretinoin 10 mg (QID) Monday-Friday
This schedule may be repeated for several weeks depending on patient tolerability and clinical responses.
There are other interferon drugs that may be considered that are discussed in some of links below:
1. Interferon responses could explain susceptibility to severe COVID-19
2. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
3. Could Interferon Drugs Help Fight COVID-19?
4. Does interferon therapy work in COVID-19?
5. What are interferons and how do they work?
6. COVID-19: lambda interferon against viral load and hyperinflammation
This experimental strategy is based on preliminary reports and case histories that primarily focus on early-stage COVID-19 patients.
Note:
Some of these reports suggest that advanced stage COVID-19 may want to avoid interferon drugs because of concerns they might worsen the proinflammatory cytokine storm, while some reports do not report this happening in small patient groups.
